Reata Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RETA Reata Pharmaceuticals Inc
BEST BEST Inc
FUPBY Fuchs Petrolub SE
JACK Jack in the Box Inc
NH NantHealth Inc
PWSC PowerSchool Holdings Inc
AEHL Antelope Enterprise Holdings Ltd
POR Portland General Electric Co
CUBI Customers Bancorp Inc
MITT AG Mortgage Investment Trust Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.

Price
Delayed
$24.32
Day's Change
-0.21 (-0.86%)
Bid
--
Ask
--
B/A Size
--
Day's High
24.75
Day's Low
23.94
Volume
(Light)

Today's volume of 32,987 shares is on pace to be much lighter than RETA's 10-day average volume of 604,440 shares.

32,987

Upcoming Events

RETA's fiscal year ends in December
There are no upcoming events for RETA

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
August 8, 2022Q2 2022 Earnings Release-$2.02-$2.13 to -$1.78-$2.00
May 10, 2022Q1 2022 Earnings Release-$2.03-$2.48 to -$1.84-$1.86
February 28, 2022Q4 2021 Earnings Release-$2.35-$2.40 to -$2.21-$1.90
November 8, 2021Q3 2021 Earnings Release-$1.97-$2.46 to -$2.04-$1.94

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.